Stent-grafting for unfavorable abdominal aortic aneurysm： a practical challenge

Background The endovascular treatment of abdominal aortic aneurysm （AAA） has improved greatly in the last 15 years. The present study aimed to evaluate the endografting experience for the treatment of unfavorable abdominal aortic aneurysm （uAAA）. Methods During December 2001 and December 2007, 41 patients with uAAA were treated with endografting using concomitant techniques. Patients were followed up for 1 to 48 months （mean 20.5 months）. Results Technical success rate was 97.6% （40/41） with 1 failure converted to open surgery for an unaccessed iliac stenosis. Nine （22.5%） type Ⅰ endoleaks （5 proximal and 4 distal） were observed on the completion angiograms and successfully corrected with aortic cuffs and iliac extensions during the procedure. Twenty-two of the planed adjunctive procedures were concomitantly performed just before endograft-implantation. There were 2 （5.0%） type Ⅰ endoleaks at 30 days; one type Ⅰ patient was treated by open conversion, another type Ⅰ patient died from a rupture before treatment in the ward, causing a 2.5% of initial mortality. The two type Ⅱ endoleaks were observed without aneurismal expansion. No buttock or leg claudication or ischemic colitis occured. During late follow-up, one additional death occurred from stroke. One new type Ⅰ endoleak was encountered from thrombocytopenia, which caused a 2.6% secondary endoleak that converted to an open surgery in the third month after a failed transabdominal banding of the aortic neck in the second month. All type Ⅱ endoleaks had disappeared in the third and sixth month. The Endografts did not present signs of material fatigue and no other type of endoleak formed. One patient presented with left limb ischemia, which underwent percutaneous transluminat angioplasty. There was no additional aneurysm rupture or any endograft imgration. Conclusion The endografting with concomitant procedures is a feasible and efficient alternative for managing unfavorable AAAs, achieving low morbidity and mortality rates and has a good clinical outcome.